Annandale Capital’s Regenxbio RGNX Stock Holding History

Annandale Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,617	Closed	-$60K	–	153
2023 Q3	$60K	Buy	+3,617	New	+$65.5K	0.01%	130

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Annandale Capital's RGNX Position: Q4 2023 in Review

Annandale Capital sold out of Regenxbio (RGNX) in Q4 2023, closing a stake of 3,617 shares — an estimated $60K sold.

Annandale Capital first reported a position in RGNX in Q3 2023 and held it in 1 quarter. The position peaked at $60K in Q3 2023. 171 funds tracked by Wall St. Rank hold RGNX as of Q4 2023.

Annandale Capital reported no remaining Regenxbio position as of Q4 2023 after selling out during the quarter.
Annandale Capital sold 3,617 Regenxbio shares in Q4 2023, an estimated $60K.
Annandale Capital first reported a position in Regenxbio in Q3 2023 and held it in 1 quarter.
Annandale Capital's Regenxbio position peaked at $60K in Q3 2023.
171 funds tracked by Wall St. Rank held Regenxbio as of Q4 2023.

Based on Annandale Capital's 13F filing for Q4 2023, filed 14 Feb 2024.